Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

NCT00961844 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Logistical problems

Conditions

Metastatic Malignant Melanoma

Interventions

BIOLOGICAL: Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion
DRUG: Temozolomide

Sponsor

Steinar Aamdal